However, multi-cohort validation confirmed that its mutation predicted survival and clinical response of NSCLC treated with ICIs, suggesting that MED12 is a specific biomarker for ICIs, not other treatment methods. The gene discussed is MED12; the disease is non-small cell lung carcinoma.